|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chung LW, Baseman A, Assikis V and Zhau
HE: Molecular insights into prostate cancer progression: The
missing link of tumor microenvironment. J Urol. 173:10–20. 2005.
View Article : Google Scholar
|
|
3
|
Zhang ML, Nie FQ, Sun M, Xia R, Xie M, Lu
KH and Li W: HOXA5 indicates poor prognosis and suppresses cell
proliferation by regulating p21 expression in non small cell lung
cancer. Tumour Biol. Dec 31–2014.Epub ahead of print.
|
|
4
|
Ma RL, Shen LY and Chen KN: Coexpression
of ANXA2, SOD2 and HOXA13 predicts poor prognosis of esophageal
squamous cell carcinoma. Oncol Rep. 31:2157–2164. 2014.PubMed/NCBI
|
|
5
|
Yamatoji M, Kasamatsu A, Yamano Y, Sakuma
K, Ogoshi K, Iyoda M, Shinozuka K, Ogawara K, Takiguchi Y, Shiiba
M, et al: State of homeobox A10 expression as a putative prognostic
marker for oral squamous cell carcinoma. Oncol Rep. 23:61–67.
2010.
|
|
6
|
Liu XH, Lu KH, Wang KM, Sun M, Zhang EB,
Yang JS, Yin DD, Liu ZL, Zhou J, Liu ZJ, et al: MicroRNA-196a
promotes non-small cell lung cancer cell proliferation and invasion
through targeting HOXA5. BMC Cancer. 12:3482012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zha TZ, Hu BS, Yu HF, Tan YF, Zhang Y and
Zhang K: Overexpression of HOXA1 correlates with poor prognosis in
patients with hepatocellular carcinoma. Tumour Biol. 33:2125–2134.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bitu CC, Destro MF, Carrera M, da Silva
SD, Graner E, Kowalski LP, Soares FA and Coletta RD: HOXA1 is
overexpressed in oral squamous cell carcinomas and its expression
is correlated with poor prognosis. BMC Cancer. 12:1462012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al Saleh S, Sharaf LH and Luqmani YA:
Signalling pathways involved in endocrine resistance in breast
cancer and associations with epithelial to mesenchymal transition
(Review). Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI
|
|
10
|
McDonnell S and Matrisian LM: Stromelysin
in tumor progression and metastasis. Cancer Metastasis Rev.
9:305–319. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chariot A and Castronovo V: Detection of
HOXA1 expression in human breast cancer. Biochem Biophys Res
Commun. 222:292–297. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho HS, Toyokawa G, Daigo Y, Hayami S,
Masuda K, Ikawa N, Yamane Y, Maejima K, Tsunoda T, Field HI, et al:
The JmjC domain-containing histone demethylase KDM3A is a positive
regulator of the G1/S transition in cancer cells via
transcriptional regulation of the HOXA1 gene. Int J Cancer.
131:E179–E189. 2012. View Article : Google Scholar
|
|
13
|
Zhan M, Qu Q, Wang G, Liu YZ, Tan SL, Lou
XY, Yu J and Zhou HH: Let-7c inhibits NSCLC cell proliferation by
targeting HOXA1. Asian Pac J Cancer Prev. 14:387–392. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao F, Bai Y, Chen Z, Li Y, Luo L, Huang
J, Yang J, Liao H and Guo L: Downregulation of HOXA1 gene affects
small cell lung cancer cell survival and chemoresistance under the
regulation of miR-100. Eur J Cancer. 50:1541–1554. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brock A, Krause S, Li H, Kowalski M,
Goldberg MS, Collins JJ and Ingber DE: Silencing HoxA1 by
intraductal injection of siRNA lipidoid nanoparticles prevents
mammary tumor progression in mice. Sci Transl Med. 6:217ra22014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wardwell-Ozgo J, Dogruluk T, Gifford A,
Zhang Y, Heffernan TP, van Doorn R, Creighton CJ, Chin L and Scott
KL: HOXA1 drives melanoma tumor growth and metastasis and elicits
an invasion gene expression signature that prognosticates clinical
outcome. Oncogene. 33:1017–1026. 2014. View Article : Google Scholar :
|
|
17
|
Lee MY and Shen MR: Epithelial-mesenchymal
transition in cervical carcinoma. Am J Transl Res. 4:1–13.
2012.PubMed/NCBI
|
|
18
|
Ohta H, Hamada J, Tada M, Aoyama T,
Furuuchi K, Takahashi Y, Totsuka Y and Moriuchi T:
HOXD3-overexpression increases integrin alpha v beta 3 expression
and deprives E-cadherin while it enhances cell motility in A549
cells. Clin Exp Metastasis. 23:381–390. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hamada Ji, Omatsu T, Okada F, Furuuchi K,
Okubo Y, Takahashi Y, Tada M, Miyazaki YJ, Taniguchi Y, Shirato H,
et al: Overexpression of homeobox gene HOXD3 induces coordinate
expression of metastasis-related genes in human lung cancer cells.
Int J Cancer. 93:516–25. 2001. View
Article : Google Scholar
|
|
20
|
Zhang X, Emerald BS, Mukhina S, Mohankumar
KM, Kraemer A, Yap AS, Gluckman PD, Lee KO and Lobie PE: HOXA1 is
required for E-cadherin-dependent anchorage-independent survival of
human mammary carcinoma cells. J Biol Chem. 281:6471–6481. 2006.
View Article : Google Scholar
|
|
21
|
Johansson N, Ahonen M and Kähäri VM:
Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci.
57:5–15. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Santarpia L, Lippman SM and El-Naggar AK:
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Edlind MP and Hsieh AC: PI3K-AKT-mTOR
signaling in prostate cancer progression and androgen deprivation
therapy resistance. Asian J Androl. 16:378–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Torii S, Yamamoto T, Tsuchiya Y and
Nishida E: ERK MAP kinase in G cell cycle progression and cancer.
Cancer Sci. 97:697–702. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kumar A, Rajendran V, Sethumadhavan R and
Purohit R: AKT kinase pathway: A leading target in cancer research.
Sci World J. 2013:7561342013. View Article : Google Scholar
|
|
26
|
Hou L, Xu B, Mohankumar KM, Goffin V,
Perry JK, Lobie PE and Liu DX: The prolactin receptor mediates
HOXA1-stimulated oncogenicity in mammary carcinoma cells. Int J
Oncol. 41:2285–2295. 2012.PubMed/NCBI
|
